Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · IEX Real-Time Price · USD
11.40
0.34 (3.07%)
May 20, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0 | 0.23 | 0.83 |
| Revenue Growth (YoY) | - | -72.90% | - |
| Gross Profit | 0 | 0.23 | 0.83 |
| Selling, General & Admin | 11.05 | 2.5 | 1.09 |
| Research & Development | 24.78 | 6.06 | 1.65 |
| Operating Expenses | 35.83 | 8.56 | 2.74 |
| Operating Income | -35.83 | -8.33 | -1.91 |
| Other Expense / Income | -0.3 | -0.05 | 0.14 |
| Pretax Income | -35.53 | -8.28 | -2.05 |
| Net Income | -35.53 | -8.28 | -2.05 |
| Net Income Common | -35.53 | -8.28 | -2.05 |
| Shares Outstanding (Basic) | 46 | 16 | 15 |
| Shares Outstanding (Diluted) | 46 | 16 | 15 |
| Shares Change | 190.80% | 2.08% | - |
| EPS (Basic) | -0.77 | -0.52 | -0.13 |
| EPS (Diluted) | -0.77 | -0.52 | -0.13 |
| Free Cash Flow Per Share | -0.67 | -0.55 | -0.01 |
| Gross Margin | - | 100.00% | 100.00% |
| Operating Margin | - | -3685.84% | -228.78% |
| Profit Margin | - | -3663.72% | -245.44% |
| Free Cash Flow Margin | - | -3869.47% | -16.67% |
| EBITDA | -35.4 | -8.28 | -2.05 |
| EBITDA Margin | - | -3661.50% | -245.44% |
| EBIT | -35.53 | -8.28 | -2.05 |
| EBIT Margin | - | -3663.72% | -245.44% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).